Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 522Neoplasms 470Carcinoma, Non-Small-Cell Lung 393Prostatic Neoplasms 302Colorectal Neoplasms 296Lung Neoplasms 259Neoplasm Metastasis 217Ovarian Neoplasms 198Leukemia, Myeloid, Acute 194Pancreatic Neoplasms 185Multiple Myeloma 172Squamous Cell Carcinoma of Head and Neck 133Recurrence 132Stomach Neoplasms 129Brain Neoplasms 126Melanoma 123Carcinoma, Hepatocellular 123Endometrial Neoplasms 120Glioblastoma 118Triple Negative Breast Neoplasms 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Hematologic Neoplasms 99Head and Neck Neoplasms 97Carcinoma, Renal Cell 96Lymphoma 93Urinary Bladder Neoplasms 90Sarcoma 90Glioma 88Lymphoma, Large B-Cell, Diffuse 81Small Cell Lung Carcinoma 80

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Lung Neuroendocrine Tumor × 90 days × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡